Today, it is essential to discriminate among HER2-positive breast cancer, HER2-low breast cancer, and breast cancer with a tumour HER2 IHC score of 0, which would not be eligible for treatment with either a traditional anti-HER2 monoclonal antibody or a HER2-based ADC. This evidence concerns the gene ERBB2 and breast cancer.